{"id":71388,"date":"2026-05-20T08:30:59","date_gmt":"2026-05-20T08:30:59","guid":{"rendered":"https:\/\/medsbase.com\/ara-290\/"},"modified":"2026-10-15T10:33:57","modified_gmt":"2026-10-15T10:33:57","slug":"ara-290","status":"publish","type":"product","link":"https:\/\/medsbase.com\/ja\/product\/ara-290\/","title":{"rendered":"ARA-290 (Cibinetide)"},"content":{"rendered":"<p><!-- medsbase-tldr-answer --><\/p>\n<div style=\"background: #fff8e1; border-left: 4px solid #f5a623; padding: 18px 22px; margin: 18px 0; border-radius: 4px;\">\n<h3 style=\"margin: 0 0 8px 0; font-size: 16px; color: #1a4a6b;\">\u30af\u30a4\u30c3\u30af\u30a2\u30f3\u30b5\u30fc \u2014 ARA-290\u3068\u306f\uff1f<\/h3>\n<p style=\"margin: 0;\"><strong>ARA-290<\/strong> (cibinetide; Helix B Surface Peptide, HBSP) is an 11-amino-acid synthetic peptide derived from helix B of erythropoietin (EPO). Designed by Brines &amp; Cerami to dissociate EPO&#8217;s cytoprotective effects from its erythropoietic effects, ARA-290 binds the innate repair receptor (IRR) \u2014 a heterocomplex of the EPO receptor and the beta-common receptor (CD131) \u2014 and triggers anti-inflammatory, anti-apoptotic, and tissue-repair signalling without elevating red-cell mass. Developed by Araim Pharmaceuticals; orphan-designated for sarcoidosis-associated small-fiber neuropathy. Supplied in 10 mg lyophilized vials.<\/p>\n<\/div>\n<div class=\"medsbase-trust-strip\" style=\"background: #f4f8fb; border: 1px solid #d8e3eb; padding: 12px 16px; margin: 16px 0; border-radius: 4px; font-size: 14px;\"><strong>MedsBase\u3067\u5f97\u3089\u308c\u308b\u3082\u306e\uff1a<\/strong> Pharmaceutical-grade lyophilized peptides &middot; HPLC &ge;99% purity (COA on request) &middot; Discreet protective packaging &middot; Worldwide peptide courier &middot; 1,400+ verified <a href=\"https:\/\/medsbase.com\/ja\/reviews\/\">\u30ab\u30b9\u30bf\u30de\u30fc\u30ec\u30d3\u30e5\u30fc<\/a><\/div>\n<p class=\"medsbase-reship-line\" style=\"font-size: 14px; color: #444; margin: 8px 0 18px;\">\ud83d\udce6 \u3059\u3079\u3066\u306e\u3054\u6ce8\u6587\u306f\u3001\u5f53\u5e97\u306e <a href=\"https:\/\/medsbase.com\/ja\/medsbase-re-shipment-assurance-policy\/\"><strong>\u518d\u767a\u9001\u4fdd\u8a3c\u30dd\u30ea\u30b7\u30fc<\/strong><\/a> \u2014 \u4e07\u304c\u4e00\u300120\u55b6\u696d\u65e5\u4ee5\u5185\u306b\u5546\u54c1\u304c\u5c4a\u304b\u306a\u3044\u5834\u5408\u306f\u3001\u518d\u767a\u9001\u3044\u305f\u3057\u307e\u3059\u3002<\/p>\n<table class=\"medsbase-spec-table\" style=\"width: 100%; border-collapse: collapse; margin: 18px 0; font-size: 14px;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 8px 12px; text-align: left; width: 30%;\">\u4ed5\u69d8<\/th>\n<th style=\"padding: 8px 12px; text-align: left;\">\u8a73\u7d30<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>CAS\u756a\u53f7<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">1208243-50-8\uff08\u30b7\u30d3\u30cd\u30c1\u30c9\uff09<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>\u30bf\u30a4\u30d7<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">\u9020\u8840\u4f5c\u7528\u306e\u306a\u3044\u3001\u30d2\u30c8\u30a8\u30ea\u30b9\u30ed\u30dd\u30a8\u30c1\u30f3\uff08EPO\uff09\u306e\u30d8\u30ea\u30c3\u30af\u30b9B\u306b\u7531\u6765\u3059\u308b11\u30a2\u30df\u30ce\u9178\u5408\u6210\u30da\u30d7\u30c1\u30c9\uff08Helix B Surface Peptide, HBSP\uff09\uff1b\u81ea\u7136\u4fee\u5fa9\u53d7\u5bb9\u4f53\uff08IRR\uff09\u30a2\u30b4\u30cb\u30b9\u30c8\uff1b\u958b\u767a\u30b3\u30fc\u30c9\uff1aARA-290\uff0f\u30b7\u30d3\u30cd\u30c1\u30c9\uff08Araim Pharmaceuticals\uff09<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>\u5206\u5b50\u5f0f<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">C<sub>51<\/sub>H<sub>84<\/sub>N<sub>16<\/sub>O<sub>21<\/sub><\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>\u5206\u5b50\u91cf<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">~1,257.4 Da<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>\u914d\u5217<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">H-pyroGlu-Glu-Gln-Leu-Glu-Arg-Ala-Leu-Asn-Ser-Ser-OH\uff08pyrEEQLERALNSS\uff09\u2014 \u30d2\u30c8\u30a8\u30ea\u30b9\u30ed\u30dd\u30a8\u30c1\u30f3\u30d8\u30ea\u30c3\u30af\u30b9B\u306e\u6c34\u76f8\u9732\u51fa\u9762\u306b\u76f8\u5f53\u3059\u308b\u76f4\u9396\u72b611\u6b8b\u57fa\u914d\u5217\u3002N\u672b\u7aef\u306e\u30b0\u30eb\u30bf\u30df\u30f3\u306f\u81ea\u767a\u7684\u306b\u30d4\u30ed\u30b0\u30eb\u30bf\u30df\u30f3\u9178\u306b\u74b0\u5316\u3057\u307e\u3059\uff08\u516c\u8868\u3055\u308c\u3066\u3044\u308b\u5206\u5b50\u91cf1,257.4 Da\u3068\u4e00\u81f4\uff09\u3002C\u672b\u7aef\u306f\u904a\u96e2\u9178\u3067\u3042\u308a\u3001\u30b8\u30b9\u30eb\u30d5\u30a3\u30c9\u7d50\u5408\u3001\u8102\u80aa\u9178\u30a2\u30b7\u30eb\u5316\u3001PEG\u5316\u306f\u3042\u308a\u307e\u305b\u3093\u3002<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>\u5f62\u614b<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">\u51cd\u7d50\u4e7e\u71e5\u7c89\u672b\uff08\u767d\u8272\u301c\u5fae\u9ec4\u8272\uff09<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>\u7d14\u5ea6<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">\u226599%\uff08HPLC\u691c\u8a3c\u6e08\u307f\u3001COA\u306f\u3054\u8981\u671b\u306b\u5fdc\u3058\u3066\u63d0\u4f9b\uff09<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>\u4fdd\u7ba1\u65b9\u6cd5<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">\u51cd\u7d50\u4e7e\u71e5\u54c1\uff1a\u30ef\u30fc\u30ad\u30f3\u30b0\u30b9\u30c8\u30c3\u30af\u306f2\uff5e8\u00b0C\uff08\u51b7\u8535\u5eab\uff09\u3001\u672a\u958b\u5c01\u30d0\u30a4\u30a2\u30eb\u306e\u9577\u671f\u4fdd\u5b58\u306f\u221220\u00b0C\u3002\u518d\u6eb6\u89e3\u5f8c\uff1a2\uff5e8\u00b0C\u3001\u7d0414\uff5e28\u65e5\u4ee5\u5185\u306b\u4f7f\u7528\u3002\u5149\u304b\u3089\u4fdd\u8b77\u3057\u3066\u304f\u3060\u3055\u3044\u3002\u518d\u6eb6\u89e3\u6db2\u306e\u51cd\u7d50\u878d\u89e3\u306e\u7e70\u308a\u8fd4\u3057\u306f\u907f\u3051\u3066\u304f\u3060\u3055\u3044\u3002<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>\u6eb6\u89e3\u6027<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">\u9759\u83cc\u6c34\uff08\u63a8\u5968\uff09\u307e\u305f\u306f\u6ec5\u83cc\u6c34\u3002\u6eb6\u89e3\u6027\u304c\u9ad8\u304f\u3001\u672a\u4fee\u98fe\u306e11\u91cf\u4f53\u306f\u7a4f\u3084\u304b\u306b\u6e26\u5dfb\u304d\u652a\u62cc\u3059\u308b\u3053\u3068\u3067\u901f\u3084\u304b\u306b\u6eb6\u89e3\u3057\u307e\u3059\u3002<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><!-- \/medsbase-tldr-answer --><\/p>\n<h2>ARA-290\u3068\u306f\u4f55\u3067\u3059\u304b\uff1f<\/h2>\n<p><strong>ARA-290<\/strong> \uff08cibinetide\uff09\u306f\u3001\u30d2\u30c8\u30a8\u30ea\u30b9\u30ed\u30dd\u30a8\u30c1\u30f3\uff08EPO\uff09\u306e\u30d8\u30ea\u30c3\u30af\u30b9B\u306e\u6c34\u6eb6\u6027\u9732\u51fa\u9762\u306b\u5bfe\u5fdc\u3059\u308b11\u30a2\u30df\u30ce\u9178\u306e\u76f4\u9396\u72b6\u5408\u6210\u30da\u30d7\u30c1\u30c9\u3067\u3059\u3002\u3053\u308c\u306f\u3001\u53e4\u5178\u7684\u306a\u30db\u30e2\u4e8c\u91cf\u4f53EPO\u53d7\u5bb9\u4f53\uff08EPOR<sub>2<\/sub>\uff09\u304c\u8d64\u8840\u7403\u7523\u751f\u3092\u4fc3\u9032\u3057\u307e\u3059\u3002ARA-290\u306f\u3001Araim Pharmaceuticals\u306eMichael Brines\u3068Anthony Cerami\u306b\u3088\u3063\u3066\u5408\u7406\u7684\u306b\u8a2d\u8a08\u3055\u308c\u3001\u6b74\u53f2\u7684\u306b\u5358\u4e00\u5206\u5b50\u306b\u7d61\u307f\u5408\u3063\u3066\u3044\u305f2\u3064\u306e\u85ac\u7406\u5b66\u7684\u306b\u7570\u306a\u308bEPO\u6d3b\u6027\u3092\u5206\u96e2\u3059\u308b\u3053\u3068\u3092\u76ee\u7684\u3068\u3057\u307e\u3057\u305f\uff1a <strong>\u8d64\u8840\u7403\u751f\u6210<\/strong> \uff08\u8840\u6813\u585e\u6813\u75c7\u306e\u30ea\u30b9\u30af\u304c\u3042\u308b\u305f\u3081\u7d44\u7e54\u4fdd\u8b77\u85ac\u3068\u3057\u3066\u306eEPO\u306e\u4f7f\u7528\u3092\u5236\u9650\u3059\u308b\u30d8\u30de\u30c8\u30af\u30ea\u30c3\u30c8\u4e0a\u6607\u4f5c\u7528\uff09\u3068 <strong>\u7d44\u7e54\u4fdd\u8b77<\/strong> (the anti-inflammatory, anti-apoptotic, and repair-promoting effects mediated by a distinct heteromeric receptor). By restricting the peptide sequence to the helix-B surface face, ARA-290 retains affinity for the <strong>\u81ea\u7136\u4fee\u5fa9\u53d7\u5bb9\u4f53\uff08IRR\uff09<\/strong> \u2014 EPO\u53d7\u5bb9\u4f53\uff08EPOR\uff09\u30b5\u30d6\u30e6\u30cb\u30c3\u30c8\u3068\u03b2\u5171\u901a\u53d7\u5bb9\u4f53\uff08\u03b2cR\u3001CD131\uff1bGM-CSF\u3001IL-3\u3001IL-5\u53d7\u5bb9\u4f53\u306e\u5171\u6709\u30b7\u30b0\u30ca\u30eb\u4f1d\u9054\u30b5\u30d6\u30e6\u30cb\u30c3\u30c8\uff09\u304b\u3089\u306a\u308b\u30d8\u30c6\u30ed\u8907\u5408\u4f53\u3067\u3042\u308a\u3001EPOR\u3078\u306e\u7d50\u5408\u3092\u6d88\u5931\u3055\u305b\u307e\u3059<sub>2<\/sub> homodimer responsible for erythropoiesis. The net effect is a peptide that produces EPO&#8217;s cytoprotective, anti-inflammatory, and neuroprotective effects in tissue without elevating hematocrit or carrying the thromboembolic and hypertensive risks that constrain therapeutic EPO use. ARA-290 has a short plasma half-life of approximately 2 minutes \u2014 the molecule is rapidly cleared \u2014 but the biological effect persists for 24\u201372 hours through downstream activation of cytoprotective signalling cascades (JAK2\/STAT3, PI3K\/Akt, anti-apoptotic Bcl-2 family upregulation). This pharmacokinetic profile is characteristic of receptor-trigger peptides where the duration of effect is driven by signal-cascade kinetics rather than by sustained plasma levels. ARA-290 has held <strong>\u30aa\u30fc\u30d5\u30a1\u30f3\u30c9\u30e9\u30c3\u30b0\u6307\u5b9a\uff08\u5e0c\u5c11\u75be\u75c5\u7528\u533b\u85ac\u54c1\u6307\u5b9a\uff09<\/strong> in the United States and the European Union for sarcoidosis-associated small-fiber neuropathy, and has been evaluated in multiple Phase 2 clinical trials in diabetic neuropathy and sarcoidosis-associated neuropathic pain. <\/p>\n<h2>\u4f5c\u7528\u6a5f\u5e8f \u2014 \u8d64\u8840\u7403\u9020\u8840\u3092\u4f34\u308f\u306a\u3044\u81ea\u7136\u4fee\u5fa9\u53d7\u5bb9\u4f53\u30a2\u30b4\u30cb\u30ba\u30e0<\/h2>\n<p>What makes ARA-290 pharmacologically distinctive is that it activates the cytoprotective limb of erythropoietin signalling while bypassing the erythropoietic limb. Three mechanisms are documented in published studies:<\/p>\n<ul>\n<li><strong>\u81ea\u7136\u4fee\u5fa9\u53d7\u5bb9\u4f53\uff08IRR\uff09\u30a2\u30b4\u30cb\u30ba\u30e0 \u2014 EPOR + \u03b2cR \/ CD131\u30d8\u30c6\u30ed\u8907\u5408\u4f53<\/strong> \u2014 \u708e\u75c7\u307e\u305f\u306f\u4f4e\u9178\u7d20\u640d\u50b7\u6761\u4ef6\u4e0b\u3067\u306f\u3001\u7d44\u7e54\u7d30\u80de\u306f\u30d9\u30fc\u30bf\u5171\u901a\u53d7\u5bb9\u4f53\uff08\u03b2cR\u3001CD131\uff09\u3092\u30a2\u30c3\u30d7\u30ec\u30ae\u30e5\u30ec\u30fc\u30c8\u3057\u3001EPO\u53d7\u5bb9\u4f53\uff08EPOR\uff09\u3068\u306e\u30d8\u30c6\u30ed\u8907\u5408\u4f53\u3092\u5f62\u6210\u3057\u307e\u3059\u3002\u3053\u306eIRR\u30d8\u30c6\u30ed\u8907\u5408\u4f53\u304cARA-290\u306e\u5206\u5b50\u6a19\u7684\u3067\u3059\u3002\u7d50\u5408\u306b\u3088\u308aJAK2\u306e\u30ea\u30f3\u9178\u5316\u3068\u4e0b\u6d41\u306eSTAT3 \/ STAT5 \/ PI3K-Akt\u306e\u6d3b\u6027\u5316\u304c\u5f15\u304d\u8d77\u3053\u3055\u308c\u3001\u6297\u30a2\u30dd\u30c8\u30fc\u30b7\u30b9\u30bf\u30f3\u30d1\u30af\u8cea\uff08Bcl-2\u3001Bcl-xL\uff09\u306e\u30a2\u30c3\u30d7\u30ec\u30ae\u30e5\u30ec\u30fc\u30b7\u30e7\u30f3\u3001\u708e\u75c7\u6027\u30b5\u30a4\u30c8\u30ab\u30a4\u30f3\u7523\u751f\uff08TNF-\u03b1\u3001IL-1\u03b2\u3001IL-6\uff09\u306e\u6291\u5236\u3001\u304a\u3088\u3073\u7d44\u7e54\u4fee\u5fa9\u30d7\u30ed\u30b0\u30e9\u30e0\u306e\u52d5\u54e1\u306b\u3064\u306a\u304c\u308a\u307e\u3059\u3002IRR\u306f\u69cb\u6210\u7684\u306b\u767a\u73fe\u3055\u308c\u308b\u306e\u3067\u306f\u306a\u304f\u3001\u640d\u50b7\u3084\u708e\u75c7\u306e\u90e8\u4f4d\u3067\u5c40\u6240\u7684\u306b\u30a2\u30c3\u30d7\u30ec\u30ae\u30e5\u30ec\u30fc\u30c8\u3055\u308c\u308b\u305f\u3081\u3001ARA-290\u306f\u3001\u5fc5\u8981\u306a\u5834\u6240\u3067\u7279\u7570\u7684\u306b\u4fee\u5fa9\u30b7\u30b0\u30ca\u30eb\u3092\u6d3b\u6027\u5316\u3059\u308b\u3001\u72b6\u6cc1\u4f9d\u5b58\u7684\u30a2\u30b4\u30cb\u30b9\u30c8\u3068\u3057\u3066\u6a5f\u80fd\u3057\u307e\u3059\u3002<\/li>\n<li><strong>\u30db\u30e2\u4e8c\u91cf\u4f53EPOR\u3078\u306e\u7d50\u5408\u306a\u3057<sub>2<\/sub> \u2014 \u8d64\u8840\u7403\u9020\u8840\u306a\u3057<\/strong> \u2014 \u9aa8\u9ac4\u8d64\u8840\u7403\u524d\u99c6\u7d30\u80de\u4e0a\u306e\u53e4\u5178\u7684\u306a\u8d64\u8840\u7403\u9020\u8840\u53d7\u5bb9\u4f53\u306f\u3001CD131\u306e\u95a2\u4e0e\u304c\u306a\u30442\u3064\u306eEPOR\u30b5\u30d6\u30e6\u30cb\u30c3\u30c8\u304b\u3089\u306a\u308b\u30db\u30e2\u4e8c\u91cf\u4f53\u3067\u3059\u3002ARA-290\u306f\u3053\u306e\u30db\u30e2\u4e8c\u91cf\u4f53\u306b\u5bfe\u3057\u3066\u7121\u8996\u3067\u304d\u308b\u7a0b\u5ea6\u306e\u89aa\u548c\u6027\u3057\u304b\u6301\u305f\u305a\u3001\u305d\u306e\u305f\u3081\u3001\u81e8\u5e8a\u8a66\u9a13\u3067\u306e\u53cd\u5fa9\u6295\u4e0e\u306b\u304a\u3044\u3066\u3082\u3001\u30d8\u30e2\u30b0\u30ed\u30d3\u30f3\u3001\u30d8\u30de\u30c8\u30af\u30ea\u30c3\u30c8\u3001\u307e\u305f\u306f\u7db2\u72b6\u8d64\u8840\u7403\u6570\u306b\u691c\u51fa\u53ef\u80fd\u306a\u5909\u5316\u306f\u751f\u3058\u307e\u305b\u3093\u3002\u3053\u308c\u306f\u3001ARA-290\u3092\u5b8c\u5168\u9577EPO\u3084\u8d64\u8840\u7403\u9020\u8840\u6d3b\u6027\u3092\u4fdd\u6301\u3057\u3066\u3044\u305f\u521d\u671f\u306e\u6539\u5909\u578bEPO\u985e\u4f3c\u4f53\uff08\u30c0\u30eb\u30d9\u30dd\u30a8\u30c1\u30f3\u3001CERA\uff09\u3068\u533a\u5225\u3059\u308b\u4e2d\u5fc3\u7684\u306a\u8a2d\u8a08\u4e0a\u306e\u7279\u5fb4\u3067\u3059\u3002<\/li>\n<li><strong>\u4e0b\u6d41\u306e\u6297\u708e\u75c7\u4f5c\u7528\u304a\u3088\u3073\u7d44\u7e54\u4fee\u5fa9\u52b9\u679c<\/strong> \u2014 In preclinical and clinical studies, ARA-290 reduces pro-inflammatory cytokine production by activated macrophages, lowers neuropathic-pain scores in small-fiber neuropathy models, accelerates corneal wound healing, reduces ischemia-reperfusion injury in renal and cardiac models, and improves glycemic control in type 2 diabetes preclinical models. The breadth of effect reflects the broad tissue distribution of the IRR under inflammatory conditions rather than a tissue-specific mechanism.<\/li>\n<\/ul>\n<p>The short plasma half-life (~2 minutes) combined with sustained biological effect (24\u201372 hours) means ARA-290 protocols typically use daily or every-other-day dosing despite the rapid molecular clearance \u2014 the pharmacodynamic duration is set by the downstream signalling cascade, not by plasma residence. Subcutaneous administration is the standard administration route and the route used in clinical development. <\/p>\n<h2>Published Evidence<\/h2>\n<p>ARA-290 is used in clinical contexts that investigate:<\/p>\n<ul>\n<li><strong>Diabetic neuropathy and small-fiber neuropathy studies<\/strong> \u2014 corneal nerve-fiber density assessment, intra-epidermal nerve-fiber density (IENFD), neuropathic-pain scoring; lead clinical studies indication, with Phase 2 trials in type 2 diabetic neuropathy showing improvement in nerve-fiber regeneration and pain scores<\/li>\n<li><strong>\u30b5\u30eb\u30b3\u30a4\u30c9\u30fc\u30b7\u30b9\u95a2\u9023\u5c0f\u5f84\u7dda\u7dad\u30cb\u30e5\u30fc\u30ed\u30d1\u30c1\u30fc<\/strong> \u2014 the indication for which ARA-290 holds US and EU orphan-drug designation; preclinical and Phase 2 studies in granulomatous inflammation models<\/li>\n<li><strong>Neuropathic pain studies<\/strong> \u2014 \u5316\u5b66\u7642\u6cd5\u8a98\u767a\u6027\u672b\u68a2\u795e\u7d4c\u969c\u5bb3\u3001\u8853\u5f8c\u795e\u7d4c\u969c\u5bb3\u3001IRR\u4ecb\u5728\u6027\u75bc\u75db\u7d4c\u8def\u306e\u6a5f\u69cb\u89e3\u660e<\/li>\n<li><strong>Ischemia-reperfusion injury studies<\/strong> \u2014 \u814e\u3001\u5fc3\u81d3\u3001\u8133\u306e\u865a\u8840\u518d\u704c\u6d41\u30e2\u30c7\u30eb\uff1b\u6297\u30a2\u30dd\u30c8\u30fc\u30b7\u30b9\u4f5c\u7528\u304a\u3088\u3073\u6297\u708e\u75c7\u4f5c\u7528\u306e\u7279\u6027\u8a55\u4fa1<\/li>\n<li><strong>Inflammation and innate immunity studies<\/strong> \u2014 \u30de\u30af\u30ed\u30d5\u30a1\u30fc\u30b8\u6975\u6027\u5316\u3001\u30b5\u30a4\u30c8\u30ab\u30a4\u30f3\u6291\u5236\u30a2\u30c3\u30bb\u30a4\u3001IRR\u4f9d\u5b58\u7684 vs IRR\u975e\u4f9d\u5b58\u7684\u30b7\u30b0\u30ca\u30eb\u89e3\u6790<\/li>\n<li><strong>Type 2 diabetes metabolic support<\/strong> \u2014 \u8840\u7cd6\u30b3\u30f3\u30c8\u30ed\u30fc\u30eb\u3001\u03b2\u7d30\u80de\u4fdd\u8b77\u3001\u30a4\u30f3\u30b9\u30ea\u30f3\u611f\u53d7\u6027\u30e1\u30ab\u30cb\u30ba\u30e0\u3068\u306e\u6bd4\u8f03<\/li>\n<li><strong>Corneal wound-healing and ophthalmic studies<\/strong> \u2014 \u89d2\u819c\u4e0a\u76ae\u5275\u50b7\u9589\u9396\u901f\u5ea6\u3001\u89d2\u819c\u306b\u304a\u3051\u308b\u795e\u7d4c\u7dda\u7dad\u306e\u518d\u751f\uff08\u6700\u3082\u5bc6\u306b\u795e\u7d4c\u652f\u914d\u3055\u308c\u308b\u7d44\u7e54\u306e\u4e00\u3064\u3067\u3001IRR\u99c6\u52d5\u578b\u4fee\u5fa9\u306e\u92ed\u654f\u306a\u30a2\u30a6\u30c8\u30d7\u30c3\u30c8\uff09<\/li>\n<\/ul>\n<p>For broader context on related anti-inflammatory and tissue-repair peptides, see <a href=\"https:\/\/medsbase.com\/ja\/bpc-157\/\">BPC-157<\/a> (\u80c3\u30da\u30d7\u30c1\u30c9\u7531\u6765\u306eMSK\/GI\u7d44\u7e54\u4fee\u5fa9), <a href=\"https:\/\/medsbase.com\/ja\/tb-500\/\">TB-500<\/a> (Thymosin Beta-4\u65ad\u7247\u3001\u5e83\u7bc4\u306a\u7d44\u7e54\u4fee\u5fa9) <a href=\"https:\/\/medsbase.com\/ja\/kpv-lysine-proline-valine\/\">KPV<\/a> (\u03b1-MSH\u7531\u6765\u306e\u6297\u708e\u75c7\u30c8\u30ea\u30da\u30d7\u30c1\u30c9)\u3002\u3059\u3079\u3066\u3092\u8868\u793a <a href=\"https:\/\/medsbase.com\/ja\/peptides\/\">\u30da\u30d7\u30c1\u30c9\u30ab\u30bf\u30ed\u30b0<\/a> \u5316\u5408\u7269\u9078\u629e\u306e\u305f\u3081\u306b\u3002 <\/p>\n<h2>\u5229\u7528\u53ef\u80fd\u306a\u529b\u4fa1\u3068\u6fc3\u5ea6<\/h2>\n<p>MedsBase stocks ARA-290 in 10 mg lyophilized vials calibrated to typical protocol lengths. Available in 10-vial, 20-vial, or 30-vial pack formats with full reconstitution guidance:<\/p>\n<table style=\"width: 100%; border-collapse: collapse; margin: 16px 0;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">\u30d0\u30a4\u30a2\u30eb\u529b\u4fa1<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">\u4ee3\u8868\u7684\u306a\u4f7f\u7528\u4f8b<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">\u30d1\u30c3\u30af\u30b5\u30a4\u30ba<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>10 mg<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Standard strength \u2014 multi-week protocols across diabetic neuropathy, ischemia-reperfusion, corneal-repair, and inflammation models; lowest per-mg cost<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10\u300120\u3001\u307e\u305f\u306f30\u30d0\u30a4\u30a2\u30eb<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>Clinical Phase 2 doses in published trials are 4 mg subcutaneous daily for diabetic neuropathy and sarcoidosis-associated neuropathy, so a single 10 mg pharmaceutical-grade vial represents a multi-day supply of clinical-equivalent dosing for in-vivo work. ARA-290 is supplied as the unmodified linear 11-mer \u2014 there is no acyl chain, no PEGylation, no disulfide bridge, and reconstitution is straightforward relative to longer or modified peptides. <\/p>\n<h2>\u6bd4\u8f03\u306e\u30dd\u30a4\u30f3\u30c8 \u2014 ARA-290 vs BPC-157<\/h2>\n<p>ARA-290 \u3068 <a href=\"https:\/\/medsbase.com\/ja\/bpc-157\/\">BPC-157<\/a> are both used in tissue-repair and anti-inflammatory studies, but the two peptides target entirely different molecular machinery. ARA-290 is an EPO-derived innate-repair-receptor agonist that drives JAK2\/STAT3 cytoprotective signalling. BPC-157 is a 15-amino-acid synthetic stable gastric pentadecapeptide derived from a fragment of human gastric juice protein BPC, acting through a complex multi-pathway mechanism including nitric oxide synthase modulation, VEGF upregulation, and growth-factor-receptor cross-talk. <\/p>\n<table style=\"width: 100%; border-collapse: collapse; margin: 16px 0;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">\u8a55\u4fa1\u9805\u76ee<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">ARA-290<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">BPC-157<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>\u7531\u6765<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">\u30d2\u30c8\u30a8\u30ea\u30b9\u30ed\u30dd\u30a8\u30c1\u30f3\u306e\u30d8\u30ea\u30c3\u30af\u30b9B\uff08HBSP\uff09<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">\u30d2\u30c8\u80c3\u6db2\u30bf\u30f3\u30d1\u30af\u8ceaBPC\u306e\u65ad\u7247<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>\u30a2\u30df\u30ce\u9178\u6570<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">11\u30a2\u30df\u30ce\u9178<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">15\u30a2\u30df\u30ce\u9178<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>\u53d7\u5bb9\u4f53\uff0f\u6a19\u7684<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">\u81ea\u7136\u4fee\u5fa9\u53d7\u5bb9\u4f53\uff08EPOR\uff0b\u03b2cR\uff0fCD131\uff09<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">\u8907\u6570\u306e\u7d4c\u8def\uff1aNO\u5408\u6210\u9175\u7d20\u3001VEGF\u3001\u6210\u9577\u56e0\u5b50\u306e\u30af\u30ed\u30b9\u30c8\u30fc\u30af<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Primary studies tissue<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">\u672b\u68a2\u795e\u7d4c\u3001\u89d2\u819c\u3001\u865a\u8840\u7d44\u7e54\u3001\u708e\u75c7\u7d44\u7e54<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">\u8171\u3001\u976d\u5e2f\u3001\u8178\u7c98\u819c\u3001\u7b4b\u8089<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>\u8d64\u8840\u7403\u7523\u751f\u4fc3\u9032\u52b9\u679c<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">\u306a\u3057\uff08\u8a2d\u8a08\u4e0a\u306e\u91cd\u8981\u306a\u7279\u5fb4\uff09<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">N\/A\uff08EPO\u7d4c\u8def\u30da\u30d7\u30c1\u30c9\u3067\u306f\u306a\u3044\uff09<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>\u8840\u6f3f\u4e2d\u534a\u6e1b\u671f<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">\u7d042\u5206\uff08\u52b9\u679c\u306f24\uff5e72\u6642\u9593\u6301\u7d9a\uff09<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">\u7d0430\u5206\uff08\u524d\u81e8\u5e8a\u3067\u7d4c\u53e3\u30d0\u30a4\u30aa\u30a2\u30d9\u30a4\u30e9\u30d3\u30ea\u30c6\u30a3\u304c\u793a\u5506\uff09<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>\u81e8\u5e8a\u958b\u767a<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">\u7b2c2\u76f8\uff08\u7cd6\u5c3f\u75c5\u6027\u30cb\u30e5\u30fc\u30ed\u30d1\u30c1\u30fc\u3001\u30b5\u30eb\u30b3\u30a4\u30c9\u30fc\u30b7\u30b9SFN\uff09\uff1b\u5e0c\u5c11\u75be\u75c5\u7528\u533b\u85ac\u54c1\u6307\u5b9a<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">\u524d\u81e8\u5e8a\u6bb5\u968e\u306e\u307f\uff08\u4e3b\u8981\u898f\u5236\u5f53\u5c40\u306e\u81e8\u5e8a\u8a66\u9a13\u306a\u3057\uff09<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>\u4fee\u98fe<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">\u975e\u4fee\u98fe\u76f4\u9396\u72b611-mer<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">\u975e\u4fee\u98fe\u76f4\u9396\u72b615-mer\uff08\u5b89\u5b9a\u306a\u9162\u9178\u5869\u307e\u305f\u306f\u30a2\u30eb\u30ae\u30f3\u9178\u5869\uff09<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>For studies focused on neuropathic-pain, peripheral-nerve regeneration, or IRR-mediated cytoprotection, ARA-290 is the targeted reference peptide. For studies focused on musculoskeletal tendon\/ligament repair or gastrointestinal mucosal healing, <a href=\"https:\/\/medsbase.com\/ja\/bpc-157\/\">BPC-157<\/a> remains the more widely-studied option. The two peptides are sometimes combined in protocols that aim to recruit complementary repair pathways across both CNS\/peripheral-nerve tissue and connective tissue. See also <a href=\"https:\/\/medsbase.com\/ja\/tb-500\/\">TB-500<\/a> \uff08Thymosin Beta-4\u30d5\u30e9\u30b0\u30e1\u30f3\u30c8\u3001\u5e83\u7bc4\u306a\u7d44\u7e54\u4fee\u5fa9\u30d9\u30f3\u30c1\u30de\u30fc\u30af\uff09\u304a\u3088\u3073 <a href=\"https:\/\/medsbase.com\/ja\/kpv-lysine-proline-valine\/\">KPV<\/a> \uff08\u03b1-MSH\u7531\u6765\u6297\u708e\u75c7\u30c8\u30ea\u30da\u30d7\u30c1\u30c9\uff09\u3002 <\/p>\n<div style=\"background: #f4f8fb; border-left: 4px solid #2c7cb0; padding: 14px 18px; margin: 18px 0;\"><strong class=\"mb-bac-water-callout\">\ud83d\udca7 BAC\u6c34\u304c\u5fc5\u8981\u3067\u3059\u304b\uff1f<\/strong> \u51cd\u7d50\u4e7e\u71e5\u54c1\u306e\u5fa9\u5143\u306b\u306f\u6ec5\u83cc\u9759\u83cc\u6c34\u304c\u5fc5\u8981\u3067\u3059\u3002\u672c\u88fd\u54c1\u3068\u4f75\u305b\u3066\u5f53\u793e\u306e <a href=\"\/ja\/bac-water\/\"><strong>BAC Water\uff08\u9759\u83cc\u6c34\uff09<\/strong><\/a> \u2014 30 mL\u30de\u30eb\u30c1\u30c9\u30fc\u30ba\u30d0\u30a4\u30a2\u30eb\u30010.9%\u30d9\u30f3\u30b8\u30eb\u30a2\u30eb\u30b3\u30fc\u30eb\u4fdd\u5b58\u3001USP\u30b0\u30ec\u30fc\u30c9\u3002<\/div>\n<h2>\u4fdd\u7ba1\u65b9\u6cd5\u3068\u518d\u6eb6\u89e3<\/h2>\n<p><strong>\u518d\u6eb6\u89e3\u524d\uff1a<\/strong> \u77ed\u671f\u4f7f\u7528\u306e\u30ef\u30fc\u30ad\u30f3\u30b0\u30b9\u30c8\u30c3\u30af\u3068\u3057\u3066\u306f\u3001\u51cd\u7d50\u4e7e\u71e5\u30d0\u30a4\u30a2\u30eb\u3092\u5143\u306e\u5305\u88c5\u306e\u307e\u307e2\uff5e8 \u00b0C\u3067\u51b7\u8535\u4fdd\u5b58\u3057\u3066\u304f\u3060\u3055\u3044\u3002\u672a\u958b\u5c01\u306e\u9577\u671f\u4fdd\u5b58\u306e\u5834\u5408\u306f\u3001\u221220 \u00b0C\u3067\u51cd\u7d50\u4fdd\u5b58\u3057\u3066\u304f\u3060\u3055\u3044\u3002\u51cd\u7d50\u4e7e\u71e5\u72b6\u614b\u306eARA-290\u306f\u3001\u51b7\u8535\u4fdd\u5b58\u3067\u6700\u592724\u304b\u6708\u9593\u3001\u221220 \u00b0C\u3067\u6700\u592736\u304b\u6708\u9593\u5b89\u5b9a\u3067\u3059\u3002\u51cd\u7d50\u4e7e\u71e5\u7c89\u672b\u306e\u51cd\u7d50\u878d\u89e3\u30b5\u30a4\u30af\u30eb\u306f\u907f\u3051\u3066\u304f\u3060\u3055\u3044\u3002ARA-290\u306f\u30b8\u30b9\u30eb\u30d5\u30a3\u30c9\u67b6\u6a4b\u3084\u30a2\u30b7\u30eb\u9396\u3092\u6301\u305f\u306a\u3044\u975e\u4fee\u98fe\u76f4\u9396\u72b6\u30da\u30d7\u30c1\u30c9\u3067\u3042\u308b\u305f\u3081\u3001\u30ab\u30b0\u30ea\u30ea\u30f3\u30c1\u30c9\u3084\u30bb\u30de\u30b0\u30eb\u30c1\u30c9\u306e\u3088\u3046\u306a\u69cb\u9020\u7684\u306b\u8907\u96d1\u306a\u30da\u30d7\u30c1\u30c9\u3068\u6bd4\u8f03\u3057\u3066\u53d6\u308a\u6271\u3044\u304c\u5bb9\u6613\u3067\u3059\u3002 <strong>\u518d\u6eb6\u89e3\u624b\u9806\uff1a<\/strong> inject bacteriostatic water down the side wall of the vial (not directly onto the lyophilized cake). For a 10 mg vial, 2.0 mL of bacteriostatic water yields a 5 mg\/mL working concentration \u2014 0.08 mL delivers 400 mcg (a 1 mg dose requires 0.2 mL); 0.8 mL delivers a clinical-equivalent 4 mg dose. Swirl gently \u2014 do not shake vigorously, as foaming entrains air and can denature peptide chains. Allow the powder to dissolve fully (typically &lt;1 minute for ARA-290) before withdrawing. Once reconstituted, store the vial at 2\u20138 \u00b0C and use within 14\u201328 days. Protect from light. Discard if cloudiness, particulates, or colour change appears. <\/p>\n<h2>\u3088\u304f\u3042\u308b\u8cea\u554f<\/h2>\n<h3>ARA-290\u306fEPO\u985e\u4f3c\u4f53\u3067\u3059\u304b\uff1f\u30d8\u30de\u30c8\u30af\u30ea\u30c3\u30c8\u3092\u4e0a\u6607\u3055\u305b\u307e\u3059\u304b\uff1f<\/h3>\n<p>ARA-290\u306f\u30a8\u30ea\u30b9\u30ed\u30dd\u30a8\u30c1\u30f3\u306e\u30d8\u30ea\u30c3\u30af\u30b9B\u306b\u7531\u6765\u3057\u307e\u3059\u304c\u3001\u7279\u306b <em>\u3057\u307e\u305b\u3093<\/em> \u30d8\u30de\u30c8\u30af\u30ea\u30c3\u30c8\u3092\u4e0a\u6607\u3055\u305b\u306a\u3044\u3088\u3046\u306b\u8a2d\u8a08\u3055\u308c\u3066\u3044\u307e\u3059\u3002EPO\u306e\u53e4\u5178\u7684\u306a\u8d64\u8840\u7403\u9020\u8840\u4f5c\u7528\u306f\u3001\u9aa8\u9ac4\u8d64\u8840\u7403\u524d\u99c6\u7d30\u80de\u4e0a\u306e\u30db\u30e2\u4e8c\u91cf\u4f53EPO\u53d7\u5bb9\u4f53\uff08EPOR<sub>2<\/sub>\uff09\u306b\u3088\u3063\u3066\u5a92\u4ecb\u3055\u308c\u307e\u3059\u3002ARA-290\u306f\u4ee3\u308f\u308a\u306b\u30d8\u30c6\u30ed\u30de\u30fc\u81ea\u7136\u4fee\u5fa9\u53d7\u5bb9\u4f53\uff08EPOR + \u03b2cR\/CD131\uff09\u306b\u7d50\u5408\u3057\u3001EPOR\u306b\u5bfe\u3059\u308b\u89aa\u548c\u6027\u306f\u7121\u8996\u3067\u304d\u308b\u7a0b\u5ea6\u3067\u3059<sub>2<\/sub>. \u3002\u516c\u8868\u3055\u308c\u3066\u3044\u308b\u7b2c2\u76f8\u8a66\u9a13\u3067\u306f\u3001\u53cd\u5fa9\u6295\u4e0e\u5f8c\u306b\u30d8\u30e2\u30b0\u30ed\u30d3\u30f3\u3001\u30d8\u30de\u30c8\u30af\u30ea\u30c3\u30c8\u3001\u7db2\u72b6\u8d64\u8840\u7403\u6570\u306b\u5909\u5316\u306f\u8a8d\u3081\u3089\u308c\u3066\u3044\u307e\u305b\u3093\u3002 <\/p>\n<h3>\u81ea\u7136\u4fee\u5fa9\u53d7\u5bb9\u4f53\uff08IRR\uff09\u3068\u306f\u4f55\u3067\u3059\u304b\uff1f<\/h3>\n<p>\u81ea\u7136\u4fee\u5fa9\u53d7\u5bb9\u4f53\u306f\u3001EPO\u53d7\u5bb9\u4f53\uff08EPOR\uff09\u30b5\u30d6\u30e6\u30cb\u30c3\u30c8\u3068\u30d9\u30fc\u30bf\u5171\u901a\u53d7\u5bb9\u4f53\uff08\u03b2cR\u3001CD131\u3068\u3057\u3066\u3082\u77e5\u3089\u308c\u3001GM-CSF\u3001IL-3\u3001IL-5\u53d7\u5bb9\u4f53\u306e\u5171\u6709\u30b7\u30b0\u30ca\u30eb\u4f1d\u9054\u30b5\u30d6\u30e6\u30cb\u30c3\u30c8\uff09\u306e\u30d8\u30c6\u30ed\u8907\u5408\u4f53\u3067\u3059\u3002IRR\u306f\u6052\u5e38\u7684\u306b\u767a\u73fe\u3059\u308b\u306e\u3067\u306f\u306a\u304f\u3001\u30b9\u30c8\u30ec\u30b9\u3092\u53d7\u3051\u305f\u7d44\u7e54\u3001\u640d\u50b7\u3057\u305f\u7d44\u7e54\u3001\u307e\u305f\u306f\u708e\u75c7\u3092\u8d77\u3053\u3057\u305f\u7d44\u7e54\u3067\u5c40\u6240\u7684\u306b\u4e0a\u65b9\u5236\u5fa1\u3055\u308c\u308b\u305f\u3081\u3001ARA-290\u306f\u5168\u8eab\u6027\u30a2\u30b4\u30cb\u30b9\u30c8\u3067\u306f\u306a\u304f\u3001\u72b6\u6cc1\u4f9d\u5b58\u7684\u306b\u7d44\u7e54\u4fee\u5fa9\u30b7\u30b0\u30ca\u30eb\u3068\u3057\u3066\u4f5c\u7528\u3057\u307e\u3059\u3002 <\/p>\n<h3>ARA-290\u304c\u30b7\u30d3\u30cd\u30c1\u30c9\u3068\u3082\u547c\u3070\u308c\u308b\u306e\u306f\u306a\u305c\u3067\u3059\u304b\uff1f<\/h3>\n<p>ARA-290\u306f\u3001Araim Pharmaceuticals\uff08\u5f53\u521d\u306e\u958b\u767a\u4f01\u696d\uff09\u306b\u3088\u308a\u4ed8\u4e0e\u3055\u308c\u305f\u958b\u767a\u30b3\u30fc\u30c9\u3067\u3059\u3002\u30b7\u30d3\u30cd\u30c1\u30c9\u306f\u3001\u81e8\u5e8a\u8a66\u9a13\u3084\u898f\u5236\u5f53\u5c40\u306e\u6587\u8108\u3067\u5f8c\u306b\u5272\u308a\u5f53\u3066\u3089\u308c\u305f\u56fd\u969b\u4e00\u822c\u540d\uff08INN\uff09\u3067\u3059\u3002\u3053\u308c\u30892\u3064\u306e\u540d\u79f0\u306f\u3001\u540c\u305811\u30a2\u30df\u30ce\u9178\u30da\u30d7\u30c1\u30c9\uff08CAS\u756a\u53f7 1208243-50-8\uff09\u3092\u6307\u3057\u307e\u3059\u3002 <\/p>\n<h3>\u8840\u6f3f\u4e2d\u534a\u6e1b\u671f\u304c\u52b9\u679c\u6301\u7d9a\u6642\u9593\u306b\u6bd4\u3079\u3066\u975e\u5e38\u306b\u77ed\u3044\u306e\u306f\u306a\u305c\u3067\u3059\u304b\uff1f<\/h3>\n<p>ARA-290\u306e\u8840\u6f3f\u4e2d\u534a\u6e1b\u671f\u306f\u7d042\u5206\u3067\u3001\u30da\u30d7\u30c1\u30c9\u306f\u5faa\u74b0\u304b\u3089\u901f\u3084\u304b\u306b\u6d88\u5931\u3057\u307e\u3059\u304c\u3001\u751f\u7269\u5b66\u7684\u52b9\u679c\u306fJAK2\\\/STAT3\u3001PI3K\\\/Akt\u3001\u6297\u30a2\u30dd\u30c8\u30fc\u30b7\u30b9\u6027Bcl-2\u30d5\u30a1\u30df\u30ea\u30fc\u30b7\u30b0\u30ca\u30eb\u30ab\u30b9\u30b1\u30fc\u30c9\u306e\u4e0b\u6d41\u6d3b\u6027\u5316\u3092\u901a\u3058\u306624\uff5e72\u6642\u9593\u6301\u7d9a\u3057\u307e\u3059\u3002\u3053\u306e\u85ac\u7269\u52d5\u614b\u30d7\u30ed\u30d5\u30a1\u30a4\u30eb\u306f\u3001\u52b9\u679c\u6301\u7d9a\u6642\u9593\u304c\u8840\u6f3f\u4e2d\u6fc3\u5ea6\u306e\u6301\u7d9a\u3067\u306f\u306a\u304f\u30b7\u30b0\u30ca\u30eb\u30ab\u30b9\u30b1\u30fc\u30c9\u306e\u52d5\u614b\u306b\u3088\u3063\u3066\u6c7a\u307e\u308b\u53d7\u5bb9\u4f53\u30c8\u30ea\u30ac\u30fc\u30da\u30d7\u30c1\u30c9\u306b\u5178\u578b\u7684\u3067\u3059\u3002 <\/p>\n<h3>How does ARA-290 compare to BPC-157 for tissue repair studies?<\/h3>\n<p>Both peptides are used in tissue-repair studies but target different machinery and different tissues. ARA-290 acts via the innate repair receptor (EPOR + CD131) and is best-characterised in peripheral-nerve, corneal, and ischemic-tissue studies. <a href=\"https:\/\/medsbase.com\/ja\/bpc-157\/\">BPC-157<\/a> acts through a multi-pathway mechanism involving nitric oxide synthase modulation and VEGF upregulation, and is best-characterised in tendon, ligament, gut mucosal, and muscle studies. Some protocols combine the two peptides to recruit complementary repair pathways. <\/p>\n<h3>\u30b5\u30eb\u30b3\u30a4\u30c9\u30fc\u30b7\u30b9\u95a2\u9023\u5c0f\u7dda\u7dad\u30cb\u30e5\u30fc\u30ed\u30d1\u30c1\u30fc\u3068\u306f\u4f55\u3067\u3059\u304b\uff1f\u307e\u305f\u3001\u306a\u305cARA-290\u306f\u305d\u308c\u306b\u5bfe\u3057\u3066\u5e0c\u5c11\u75be\u75c5\u7528\u533b\u85ac\u54c1\u6307\u5b9a\u3092\u53d7\u3051\u3066\u3044\u308b\u306e\u3067\u3059\u304b\uff1f<\/h3>\n<p>Sarcoidosis is a granulomatous inflammatory disease that produces a debilitating small-fiber neuropathy (SFN) in a substantial fraction of affected patients. ARA-290 holds US FDA and EU EMA orphan-drug designation for sarcoidosis-associated SFN, reflecting the rarity of the indication and the absence of other targeted treatments. The orphan designation supports clinical studies but does not constitute approval \u2014 ARA-290 is investigational at the time of this writing. <\/p>\n<h3>What is the standard dose for ARA-290?<\/h3>\n<p>Published Phase 2 clinical trials have used 2\u20134 mg subcutaneous daily for diabetic neuropathy and sarcoidosis-associated SFN. Preclinical animal studies have used wider dose ranges depending on model and tissue. Users should determine dose ranges from peer-reviewed literature appropriate to their specific protocol. <\/p>\n<h3>ARA-290\u306f\u30b8\u30b9\u30eb\u30d5\u30a3\u30c9\u307e\u305f\u306f\u30a2\u30b7\u30eb\u4fee\u98fe\u306e\u305f\u3081\u306b\u7279\u5225\u306a\u53d6\u308a\u6271\u3044\u304c\u5fc5\u8981\u3067\u3059\u304b\uff1f<\/h3>\n<p>\u3044\u3044\u3048\u3002ARA-290\u306f\u3001\u30b8\u30b9\u30eb\u30d5\u30a3\u30c9\u7d50\u5408\u3001\u8102\u80aa\u9178\u30a2\u30b7\u30eb\u5316\u3001PEG\u5316\u306e\u3044\u305a\u308c\u3082\u6301\u305f\u306a\u3044\u3001\u4fee\u98fe\u3055\u308c\u3066\u3044\u306a\u3044\u76f4\u9396\u72b6\u306e11\u30a2\u30df\u30ce\u9178\u30da\u30d7\u30c1\u30c9\u3067\u3059\u3002\u518d\u69cb\u6210\u3068\u53d6\u308a\u6271\u3044\u306f\u7c21\u5358\u3067\u3001\u7a4f\u3084\u304b\u306b\u65cb\u56de\u3055\u305b\u308b\u3060\u3051\u3067\u51cd\u7d50\u4e7e\u71e5\u7c89\u672b\u304c\u7d041\u5206\u3067\u6eb6\u89e3\u3057\u307e\u3059\u3002\u3053\u308c\u306b\u5bfe\u3057\u3001\u30ab\u30b0\u30ea\u30ea\u30f3\u30c1\u30c9\uff08\u30a2\u30b7\u30eb\u9396\uff0b\u30b8\u30b9\u30eb\u30d5\u30a3\u30c9\u7d50\u5408\uff09\u3001\u30bb\u30de\u30b0\u30eb\u30c1\u30c9\uff08\u30a2\u30b7\u30eb\u9396\uff09\u3001\u30a4\u30f3\u30b9\u30ea\u30f3\u30af\u30e9\u30b9\u306e\u30da\u30d7\u30c1\u30c9\u306a\u3069\u69cb\u9020\u7684\u306b\u8907\u96d1\u306a\u30da\u30d7\u30c1\u30c9\u3067\u306f\u3001\u518d\u69cb\u6210\u306b\u3088\u308a\u9577\u3044\u5e73\u8861\u5316\u6642\u9593\u304c\u5fc5\u8981\u3067\u3059\u3002 <!-- medsbase-related-alts-v1 --><\/p>","protected":false},"excerpt":{"rendered":"<p>\u2705 \u9020\u8840\u4f5c\u7528\u3092\u6301\u305f\u306a\u3044EPO\u7531\u6765\u306e11\u30a2\u30df\u30ce\u9178\u30da\u30d7\u30c1\u30c9<br \/>\n\u2705 \u81ea\u7136\u4fee\u5fa9\u53d7\u5bb9\u4f53\uff08EPOR + CD131\uff09\u30a2\u30b4\u30cb\u30b9\u30c8<br \/>\n\u2705 \u6297\u708e\u75c7\u3001\u795e\u7d4c\u4fdd\u8b77\u3001\u7d44\u7e54\u4fee\u5fa9\u306e\u30b7\u30b0\u30ca\u30eb\u4f1d\u9054<br \/>\n\u2705 \u30d8\u30de\u30c8\u30af\u30ea\u30c3\u30c8\u4e0a\u6607\u306a\u3057\uff08\u5b8c\u5168EPO\u3068\u306e\u91cd\u8981\u306a\u8a2d\u8a08\u5dee\uff09<br \/>\n\u2705 \u30b5\u30eb\u30b3\u30a4\u30c9\u30fc\u30b7\u30b9\u95a2\u9023\u5c0f\u5f84\u7dda\u7dad\u30cb\u30e5\u30fc\u30ed\u30d1\u30c1\u30fc\u306b\u5bfe\u3059\u308b\u30aa\u30fc\u30d5\u30a1\u30f3\u6307\u5b9a<\/p>\n<p><strong>ARA-290<\/strong> \u5408\u6210\u30da\u30d7\u30c1\u30c9\u5316\u5408\u7269\u3092\u542b\u307f\u307e\u3059\u3002<\/p>","protected":false},"featured_media":71396,"comment_status":"open","ping_status":"closed","template":"","meta":[],"product_brand":[],"product_cat":[5426],"product_tag":[6461,6462,5441],"class_list":["post-71388","product","type-product","status-publish","has-post-thumbnail","product_cat-peptides","product_tag-ara-290","product_tag-cibinetide","product_tag-peptide","first","instock","shipping-taxable","purchasable","product-type-variable","has-default-attributes"],"acf":[],"_links":{"self":[{"href":"https:\/\/medsbase.com\/ja\/wp-json\/wp\/v2\/product\/71388","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medsbase.com\/ja\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/medsbase.com\/ja\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/medsbase.com\/ja\/wp-json\/wp\/v2\/comments?post=71388"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medsbase.com\/ja\/wp-json\/wp\/v2\/media\/71396"}],"wp:attachment":[{"href":"https:\/\/medsbase.com\/ja\/wp-json\/wp\/v2\/media?parent=71388"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/medsbase.com\/ja\/wp-json\/wp\/v2\/product_brand?post=71388"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/medsbase.com\/ja\/wp-json\/wp\/v2\/product_cat?post=71388"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/medsbase.com\/ja\/wp-json\/wp\/v2\/product_tag?post=71388"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}